Study of ACVBP Plus Rituximab in Previously Untreated Patients Aged From 18 to 59 Years With High Risk Diffuse Large B-cell Lymphoma (Age-adjusted IPI = 2-3).
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Bleomycin; Cortisone; Cyclophosphamide; Doxorubicin; Rituximab; Vindesine
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 02 Sep 2015 Biomarkers information updated
- 25 Jul 2007 End date updated from NCT.
- 28 Jun 2007 Status changed from recruiting to in progress.